BeyondSpring to Present at Two Upcoming Scientific Conferences in December
BeyondSpring to present at the 62nd American Society of Hematology (ASH) Annual Meeting and at the 2020 San Antonio Breast
Read morenews
Hepatocellular Carcinoma Drugs Market 2020-2024 | Forecasting Strategy to Undergo a Paradigm Shift From Crisis to New Normal During COVID-19 Pandemic | Technavio
LONDON–(BUSINESS WIRE)–#GlobalHepatocellularCarcinomaDrugsMarket–The hepatocellular carcinoma drugs market is poised to grow by USD 85.10 million during 2020-2024, progressing at a CAGR
Read moreSyneos Health Announces Closing of Offering of $600.0 Million of Senior Notes Due 2029
MORRISVILLE, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) — Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only
Read moreCodexis and Casdin Capital Launch SynBio Innovation Accelerator
Combines Codexis’ R&D and commercialization platform with Casdin Capital’s investment expertise to invest in and support innovative early stage life
Read moreCodexis and Casdin Capital Launch SynBio Innovation Accelerator
Combines Codexis’ R&D and commercialization platform with Casdin Capital’s investment expertise to invest in and support innovative early stage life
Read moreCodexis and Casdin Capital Launch SynBio Innovation Accelerator
Combines Codexis’ R&D and commercialization platform with Casdin Capital’s investment expertise to invest in and support innovative early stage life
Read moreCodexis and Casdin Capital Launch SynBio Innovation Accelerator
Combines Codexis’ R&D and commercialization platform with Casdin Capital’s investment expertise to invest in and support innovative early stage life
Read moreReata Provides Update on Omaveloxolone Program for Patients with Friedreich’s Ataxia
PLANO, Texas, Nov. 24, 2020 (GLOBE NEWSWIRE) — Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage
Read moreReata Provides Update on Omaveloxolone Program for Patients with Friedreich’s Ataxia
PLANO, Texas, Nov. 24, 2020 (GLOBE NEWSWIRE) — Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage
Read moreReata Provides Update on Omaveloxolone Program for Patients with Friedreich’s Ataxia
PLANO, Texas, Nov. 24, 2020 (GLOBE NEWSWIRE) — Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage
Read more